Menu Schließen

Multiple Achievements
in Recent Years

Dialysis is a lifesaving treatment, but also exerts adverse effects on different organs, such as the cardiovascular system.

Peritoneal Dialysis has better survival outcome during the first 3 to 5 years, but this therapy is limited in time, due to peritoneal fibrosis. Therefore, the WHO and Western health authorities recommend starting dialysis treatment with PD and switching to HD as peritoneal ultrafiltration efficacy attenuates.

PD shows better survival rates for ESRD patients
Source: Annual Data Report, USRDS 2020, End Stage Renal Disease: Chapter 5
PD reduces body fluid and uremic toxins through an osmotic driver. In current PD solutions, the glucose is present at relatively high osmotic pressure. Furthermore, glucose itself represents a metabolic challenge.

Opterion applies different strategies to reduce different side effects of PD:

  • Reducing osmotic pressure during PD dwells without compromising ultrafiltration efficacy.
  • Eliminating glucose from PD solutions to avoid metabolic syndrome.
  • Decrease cytotoxicity of PD solutions to the peritoneum, reducing fibrosis, with the goal to prolong PD treatment time.
  • Clinical studies will show whether the Opterion PD solution may also reduce systemic inflammation.

Osmotic Driver (ODR):

  • Opterion develops a new osmotic driver for PD (Opt100), composed of short glucose polymers (~5kDa) and maltose. Opt100 can be applied for short and long dwells1. Different Opt100 concentrations allow to adapt Ultrafiltration efficacy, comparable to glucose-based PD solutions. But Opt100 contains less than 0.1% glucose1, thereby representing less or no metabolic challenge as compared to current PD treatments.
  • Opt100 is the first osmotic driver allowing all dwells of a PD patient to be run by a glucose free PD solution (reduced metabolic challenge).
  • All ODR components have previously been applied in humans at very comparable concentrations with no tolerability issues.
  • Opt100 manufacturing and toxicology studies to be established in 2020/21.
  • Manufacturing partners for preclinical and clinical trials supply engaged.

    1 Grentzmann & Steinhauer 2018, WO2018146345 (A1)


Biocompatibility-enhancing Agent (BCA):

  • Cell-culture of primary human peritoneal mesothelial cells show decreased cytotoxicity of PD-solutions in presence of different stilbenoids, including Resveratrol2.
  • Resveratrol reduces vascular endothelial growth factor (VEGF) in a rat PD model2.
  • Stilbenoids are solubilized and stabilized by saccharide containing solutions such as Opt1003.
  • Resveratrol is an established food additive and has GRAS* status in the USA.


  • 2 Grentzmann 2017, WO2017013120 (A1)
    3 Grentzmann 2017, WO2017013121 (A1)
    * GRAS: generally recognized as safe

Formulation for ODR1 & BCA2

1New Osmotic Driver; 2Biocompatibility Enhancing Agent

Animal studies on increased Ultrafiltration efficacy of ODR

Cell & Animal studies on decreased cytotoxicity and inflammation on BCA

API3 specifications for ODR & BCA

3Active Pharmaceutical Ingredient

Trial designs and budgeting completed

Manufacturing partners for preclinical and clinical trials supply

Internal genomic analysis identified new PD4 markers (supports patent strategy)

4Peritoneal Dialysis

Positive EPO5 feedback on ODR & BCA patent applications:
- 2 patents granted in Japan
- 1 patent granted in Australia

Opterion obtained SME Status at EMA6

6European Medicines Agency

Stefan Wohlfeil

Board Member
Stefan Wohlfeil, MD, has over 35 years of experience in the Pharma and Biotech industry. Most recently he was Chief Medical Officer and Head of R&D at Vifor Pharma with responsibility for preclinical and clinical R&D, regulatory and medical affairs as well as drug safety. Prior to that he was Global Head Clinical Research & Pharmacology at Novartis and Bayer. He also has experience as founder and CEO of two start-up companies in the oncology area, one of which was based in Japan. Stefan started his career at Bayer Pharma, where he worked for over 20 years in discovery research and preclinical and clinical development in Germany, USA and Japan. Stefan holds a Medical Doctor’s degree from the University of Düsseldorf, Germany.

Andreas Schmidt

CFO / Board

Andreas Schmid has more than 25 years of experience in Finance in the Life Sciences. He worked as a Pharma Analyst at Merrill Lynch and also has experience in fund raising as well as business development.

During the span of his career Andreas was one of the highest-ranked dialysis and generic pharma analysts, with special expertise in European and CEE/emerging markets. His coverage universe included companies such as Fresenius/FMC (Germany), Gambro (Sweden), Stada (Germany) and Aspen (South Africa). Furthermore, he played a major part in the IPOs of Zentiva (Czech Republic) and Hikma (Jordan). Andreas has also been active as a speaker at various industry conferences, for example in New York, Frankfurt, but also in Warsaw and other Eastern European countries.

In addition, Andreas works as finance lecturer at the Hochschule Pforzheim and is a board member of the German shareholder association SdK.

Ricardo Cordero

Vice Chairman
Dr Ricardo Cordero, PhD, serves as Vice Chairman of Opterion Health since 2016. Ricardo has over 30 years of experience in the Financial Services Industry where he held various senior positions, for example as CEO of BZ Bank, Managing Partner at Reichmuth & Co Investmentfonds AG, Co-founder and Co-CEO at BWO Bank, etc. Further, he is a passionate and experienced private Swiss investor and holds various investments in the Life Science, Technology and high-end Consumer Goods industry.

David Ebsworth

Dr David Ebsworth, PhD, has been Chairman of Opterion Health since December 2016. David has over 40 years of experience in the Pharma, Healthcare and Biotech industry. David is a past CEO of Galenica, Vifor Pharma as well as Oxford GlycoSciences and past global head of the Pharmaceutical Division of Bayer. He has chaired several private and public companies and has served on numerous boards as either chairman of the audit, remuneration or nominations and governance committees. David is currently Chairman of Verona Pharma and Actimed Therapeutics.

Guido Grentzmann

CEO / CSO / Board
Dr Guido Grenzmann, PhD, is the founder of Opterion Health and has more than 25 years of experience in Pharma R&D and Project Management. After academic work on bacterial and viral mechanisms of translational regulation, he became Group Leader Molecular Biology/Genomics at Pfizer and Director Biochemistry/GeneProfiling at Altana Pharma where he worked in Discovery of inflammation in respiratory diseases. In 2007 he founded PBS PharmaBioServices providing contract research and consulting mainly in inflammatory diseases, in multiple therapeutic domains. 2012, Guido founded Opterion, with the aim to develop a new PD solution, to decrease side-effects of this promising therapy.